Stock GMAB GENMAB A/S
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Genmab A/S Nasdaq

Equities

GMAB

US3723032062

Market Closed - Nasdaq
Other stock markets
 01:30:00 18/05/2024 am IST 		5-day change 1st Jan Change
29.98 USD +1.11% Intraday chart for Genmab A/S +4.06% -5.84%
15/05 Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation' MT
15/05 Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50% MT

Evolution of the average Target Price on Genmab A/S

Price target over the last 5 years

History of analyst recommendation changes

53b64d598c0.CjPJLfFhv2HDcUIftLEEF2Jpq7-g_RdGORd-hn36fyY.aR6fZMAX0kyFAydI9_VFRFcj4NLotlIcf3I_4yWPMVJdXP1nuDCSAvs2Ew~0411ad8569b3079f1866a90e7079b31c

Analyst Recommendations on Genmab A/S

GENMAB : A good start to 2024; guidance unchanged Alphavalue
GENMAB : Genmab is available at a bargain price Alphavalue
BMO Capital Upgrades Genmab to Outperform From Market Perform, Adjusts Price Target to $48 From $46 MT
RBC Cuts Price Target on Genmab to DKK2,400 From DKK2,500, Keeps Sector Perform Rating MT
GENMAB : A profitability miss but the market welcomed the better-than-expected sales guidance + share buybacks Alphavalue
HC Wainwright Raises Price Target on Genmab to $50 From $49, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Genmab to $32 From $33, Maintains Underweight Rating MT
HC Wainwright Adjusts Price Target on Genmab to $49 From $51, Maintains Buy Rating MT
GENMAB : Better-than-expected Q3; lower-end of sales guidance upgraded Alphavalue
GENMAB : Factoring in some caution Alphavalue
BTIG Raises Price Target on Genmab to $46 From $44, Maintains Buy Rating MT
GENMAB : Incorporating R&D priorities; attractiveness remains intact Alphavalue
BTIG Starts Genmab at Buy With $44 Price Target MT
GENMAB : A good Q2 + improved sales guidance Alphavalue
AbbVie, Genmab Say Phase 1/2 Trial of Epcoritamab in Follicular Lymphoma Patients Showed 82% of Overall Response Rate MT
Genmab Says Epcoritamab Drug Combination Shows 98% Overall Response Rate in Phase 1/2 Trial in Follicular Lymphoma MT
HC Wainwright Adjusts Price Target on Genmab to $51 From $47, Keeps Buy Rating MT
HC Wainwright Adjusts Price Target on Genmab to $47 From $46, Maintains Buy Rating MT
GENMAB : Mixed Q1; attractiveness remains intact, despite profitability miss Alphavalue
GENMAB : Promising 2022; even the softer 2023 guidance isn’t a worry Alphavalue
HC Wainwright Adjusts Price Target on Genmab to $46 From $51, Maintains Buy Rating MT
Morgan Stanley Trims Price Target on Genmab to $33 From $34, Maintains Underweight Rating MT
GENMAB : Promising 2022; even softer 2023 guidance isn’t a worry Alphavalue
Morgan Stanley Adjusts Price Target on Genmab to $34 From $35, Keeps Underweight Rating MT
SVB Securities Adjusts Price Target on Genmab A/S to $36 From $33, Maintains Market Perform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
2,041 DKK
Average target price
2,470 DKK
Spread / Average Target
+21.01%
High Price Target
3,000 DKK
Spread / Highest target
+46.99%
Low Price Target
1,600 DKK
Spread / Lowest Target
-21.61%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Genmab A/S

alphavalue Anas Patel
BMO Capital
RBC Capital Markets
HC Wainwright
Morgan Stanley
BTIG
SVB Securities LLC
William Blair & Co.
DNB Markets
Credit Suisse
Bryan, Garnier & Co.
Cowen
SVB Leerink
Guggenheim
Berenberg Bank
Jefferies & Co.
Deutsche Bank Securities
Danske Bank Group

Ratings for Genmab A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. GMAB Stock
  4. GMAB Stock
  5. Consensus Genmab A/S
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW